EUVIMEDEUVIMED entdecken
Crossref

Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors

Ying Yan Zhong iD, Angelyn Anton iD, Owen Xie iD, Natalie Tan, Sophie O'Haire iD, Sam Maleki iD, Andrisha-Jade Inderjeeth iD, Phillip Parente, Lavinia Spain, Peter Gibbs iD, Ben Tran iD

JCO Oncology Practice · 2024

DOI: 10.1200/op.24.00036 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, 2024. Verfasst von Ying Yan Zhong und 10 weiteren Autor:innen. Beteiligte Einrichtung: Peter MacCallum Cancer Centre, Melbourne, VIC, Australia. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Drug Interactions, Comorbidity, Androgen Receptor Antagonists. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 38 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Androgen receptor pathway inhibitors (ARPIs) are widely prescribed in metastatic castration-resistant prostate cancer (mCRPC). Real-world frequencies and potential impacts of comorbidities and concomitant medication (conmed) interactions with ARPIs are not well described. METHODS Patients receiving ARPIs for mCRPC were identified from the electronic Prostate Cancer Australian Database (ePAD). Demographics, clinicopathologic characteristics, and outcome data were extracted. Conmeds and comorbidities were collected from medical records. Potential interacting comorbidities were defined from trial and post-trial data. Clinically significant drug-drug interactions (DDIs) were identified using UpToDate Lexicomp and Stockley's databases. Patient characteristics, comorbidity interactions, DDIs, and outcomes were analyzed. RESULTS Two hundred thirty-five patients received first- or second-line ARPIs for mCRPC from 2012 to 2021, with a median follow-up of 27 months. One hundred sixteen received abiraterone acetate (AAP) and 135 received enzalutamide (ENZ). The median age was 74 years, and the median number of conmeds was 4. Clinically significant DDIs occurred in 55 (47%) AAP patients and 90 (67%) ENZ patients. Only 5% of DDIs were predicted to affect ARPI pharmacokinetics (PK) or pharmacodynamics, whereas 95% were predicted to impact conmed PK or increase toxicity risk. In patients receiving ENZ, DDIs were associated with lower PSA50 (50% v 74%, P = .04) and poorer overall survival (28 v 45 months, P = .04), although statistical significance was not maintained on multivariate analysis. No significant survival differences were seen with DDIs in patients receiving AAP. Potential interactions between comorbidities and ARPI were present in 72% on AAP and 14% on ENZ with no significant associated survival differences. CONCLUSION DDIs and drug-comorbidity interactions in real-world patients receiving ARPIs for mCRPC are common and may affect outcomes. Ongoing clinician education regarding DDIs is necessary to optimize patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDrug InteractionsComorbidityAndrogen Receptor AntagonistsHumansMaleAgedAged, 80 and overMiddle AgedNeoplasm MetastasisPhenylthiohydantoinBenzamidesNitriles

Substanzen

Androgen Receptor AntagonistsPhenylthiohydantoinenzalutamideBenzamidesNitriles

Autor:innen und Institutionen

  • Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Eastern Health, Melbourne, VIC, Australia.
  • Walter and Eliza Hall Institute of Medical Research, Melbourne, VIC, Australia.
  • Monash University, Melbourne, VIC, Australia.
  • Western Health, Melbourne, VIC, Australia.

ORCID-Profile: Ying Yan Zhong, Angelyn Anton, Owen Xie, Sophie O'Haire, Sam Maleki, Andrisha-Jade Inderjeeth, Peter Gibbs, Ben Tran

Zitieren

APA

Zhong, Y. Y., Anton, A., Xie, O., Tan, N., O'Haire, S., Maleki, S., Inderjeeth, A. J., Parente, P., Spain, L., Gibbs, P., & Tran, B. (2024). Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors. JCO Oncology Practice. https://doi.org/10.1200/op.24.00036

Vancouver

Zhong YY, Anton A, Xie O, Tan N, O'Haire S, Maleki S, et al. Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors. JCO Oncology Practice. 2024. doi:10.1200/op.24.00036

BibTeX
@article{Zhong2024,
  author = {Zhong, Ying Yan and Anton, Angelyn and Xie, Owen and Tan, Natalie and O'Haire, Sophie and Maleki, Sam and Inderjeeth, Andrisha-Jade and Parente, Phillip and Spain, Lavinia and Gibbs, Peter and Tran, Ben},
  title = {Impact of Comorbidities and Drug Interactions in Patients With Metastatic Castration-Resistant Prostate Cancer Receiving Androgen Receptor Pathway Inhibitors},
  journal = {JCO Oncology Practice},
  year = {2024},
  doi = {10.1200/op.24.00036}
}
Kostenlos starten →